Related references
Note: Only part of the references are listed.Poly (ADP-ribose) polymerase 1 (PARP1) inhibition promotes pulmonary metastasis of osteosarcoma by ezrin phosphorylation
Fangfei Li et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2022)
Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies
Antonella Padella et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)
Mammalian AKT, the Emerging Roles on Mitochondrial Function in Diseases
Xiaoxian Xie et al.
AGING AND DISEASE (2022)
SARS-CoV-2 infection induces a pro-inflammatory cytokine response through cGAS-STING and NF-κB
Christopher J. Neufeldt et al.
COMMUNICATIONS BIOLOGY (2022)
The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy
Brigida Anna Maiorano et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Beyond BRCA: The Emerging Significance of DNA Damage Response and Personalized Treatment in Pancreatic and Prostate Cancer Patients
Bruna Dalmasso et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy
Eugene Y. Chiang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Functional assessment of the cell-autonomous role of NADase CD38 in regulating CD8+ T cell exhaustion
Kaili Ma et al.
ISCIENCE (2022)
PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors
Anna D. Staniszewska et al.
ONCOIMMUNOLOGY (2022)
The Current State of the Art in PARP Inhibitor-Based Delivery Nanosystems
Lisha Cai et al.
PHARMACEUTICS (2022)
PARP1: Liaison of Chromatin Remodeling and Transcription
Wen Zong et al.
CANCERS (2022)
Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical Implications
Carlos Wagner S. Wanderley et al.
FRONTIERS IN IMMUNOLOGY (2022)
Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint
TingTing Tang et al.
PHARMACOLOGY & THERAPEUTICS (2021)
CD155/TIGIT, a novel immune checkpoint in human cancers
Lu Liu et al.
ONCOLOGY REPORTS (2021)
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
Lucia Musacchio et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer
Bradley J. Monk et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)
Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer
Mohamed A. Ghonim et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy
Minlin Jiang et al.
ACTA PHARMACEUTICA SINICA B (2021)
Inflammatory Cytokines in Cancer: Comprehensive Understanding and Clinical Progress in Gene Therapy
Tianxia Lan et al.
CELLS (2021)
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
Susana Banerjee et al.
LANCET ONCOLOGY (2021)
TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells
Liang Mao et al.
ORAL ONCOLOGY (2021)
TIGIT/CD226 Axis Regulates Anti-Tumor Immunity
Jinah Yeo et al.
PHARMACEUTICALS (2021)
CD38 identifies pre-activated CD8+T cells which can be reinvigorated by anti-PD-1 blockade in human lung cancer
Pin Wu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer
Xue-lin Zou et al.
FRONTIERS IN IMMUNOLOGY (2021)
TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment
Shusuke Kawashima et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
PARP Inhibitors and Haematological Malignancies-Friend or Foe?
Kathryn A. Skelding et al.
CANCERS (2021)
Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
Hongmei Wang et al.
FRONTIERS IN ONCOLOGY (2021)
OA07.07 PARP1 Inhibitors Enhanced IFNγ-Induced PD-L1 Expression in LKB1-Mutant Lung Cancer
X. Bai et al.
Journal of Thoracic Oncology (2021)
Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance
Desh Deepak Singh et al.
BIOMEDICINES (2021)
TBK1 recruitment to STING activates both IRF3 and NF-κB that mediate immune defense against tumors and viral infections
Seoyun Yum et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
DNAM-1 regulates Foxp3 expression in regulatory T cells by interfering with TIGIT under inflammatory conditions
Kazuki Sato et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer
Chao Dong et al.
FRONTIERS IN PHARMACOLOGY (2021)
Clinical Insights Into Novel Immune Checkpoint Inhibitors
Jii Bum Lee et al.
FRONTIERS IN PHARMACOLOGY (2021)
The Key Role of NAD+ in Anti-Tumor Immune Response: An Update
Fabio Morandi et al.
FRONTIERS IN IMMUNOLOGY (2021)
Neoantigen: A New Breakthrough in Tumor Immunotherapy
Zheying Zhang et al.
FRONTIERS IN IMMUNOLOGY (2021)
In vivo visualization of PARP inhibitor pharmacodynamics
Elizabeth S. McDonald et al.
JCI INSIGHT (2021)
First-line (1L) maintenance therapy with niraparib (nira) plus pembrolizumab (pembro) vs placebo plus pembro in advanced/metastatic non-small cell lung cancer (NSCLC): Phase III ZEAL-1L study
S. S. Ramalingam et al.
ANNALS OF ONCOLOGY (2021)
The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer
William Freed-Pastor et al.
CANCER CELL (2021)
Pamiparib: First Approval
Anthony Markham
DRUGS (2021)
Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy followed by durvalumab in unresectable, locally advanced, stage III non-small cell lung cancer: KEYLYNK-012.
Salma K. Jabbour et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
NAD+ supplement potentiates tumor-killing function by rescuing defective TUB-mediated NAMPT transcription in tumor-infiltrated T cells
Yuetong Wang et al.
CELL REPORTS (2021)
Leveraging NKG2D Ligands in Immuno-Oncology
Mercedes Beatriz Fuertes et al.
FRONTIERS IN IMMUNOLOGY (2021)
FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients
Ye Wang et al.
FRONTIERS IN ONCOLOGY (2021)
PARP inhibitors promote stromal fibroblast activation by enhancing CCL5 autocrine signaling in ovarian cancer
Xiaoting Li et al.
NPJ PRECISION ONCOLOGY (2021)
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial
Antonio Gonzalez Martin et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)
The cGAS-STING pathway as a therapeutic target in inflammatory diseases
Alexiane Decout et al.
NATURE REVIEWS IMMUNOLOGY (2021)
Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors
Wenchao Ji et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
CD155: A Multi-Functional Molecule in Tumor Progression
Rosa Molfetta et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Combination Therapy with Radiation and PARP Inhibition Enhances Responsiveness to Anti-PD-1 Therapy in Colorectal Tumor Models
Steven N. Seyedin et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies
Jose Yelamos et al.
CANCERS (2020)
Acquired Resistance to Immune Checkpoint Inhibitors
Adam J. Schoenfeld et al.
CANCER CELL (2020)
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
Erika J. Lampert et al.
CLINICAL CANCER RESEARCH (2020)
Randomized phase III study of first-line pembrolizumab plus pemetrexed/platinum followed by pembrolizumab and maintenance olaparib versus pemetrexed in patients with metastatic nonsquamous non-small cell lung cancer (NSCLC): KEYLYNK-006.
Jhanelle Elaine Gray et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results.
Evan Y. Yu et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC).
Hope S. Rugo et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
Stergios Boussios et al.
DRUGS IN R&D (2020)
CD226hiCD8+ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy
Hyung-seung Jin et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Emerging Therapeutic Implications of STK11 Mutation: Case Series
Bahar Laderian et al.
ONCOLOGIST (2020)
Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer
Alejandra Martinez et al.
CANCERS (2020)
CD226: An Emerging Role in Immunologic Diseases
Zhiyi Huang et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline
William P. Tew et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Randomized, placebo-controlled phase III study of 1L pembrolizumab (Pembro) plus carboplatin/taxane followed by pembro with or without maintenance olaparib in patients (Pts) with metastatic squamous non-small cell lung cancer (sqNSCLC): KEYLYNK-008
J. E. Gray et al.
ANNALS OF ONCOLOGY (2020)
Exhausted CD8+ T cells exhibit low and strongly inhibited TCR signaling during chronic LCMV infection
Ioana Sandu et al.
NATURE COMMUNICATIONS (2020)
Genetic characterization of pancreatic cancer patients and prediction of carrier status of germline pathogenic variants in cancer-predisposing genes
Keijiro Mizukami et al.
EBIOMEDICINE (2020)
Beyond BRCA1 and BRCA2: Deleterious Variants in DNA Repair Pathway Genes in Italian Families with Breast/Ovarian and Pancreatic Cancers
Aldo Germani et al.
JOURNAL OF CLINICAL MEDICINE (2020)
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Maddison Rose et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy
Robert M. Samstein et al.
NATURE CANCER (2020)
PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers
Elizabeth K. Lee et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The NAD-dependent deacetylase SIRT2 regulates T cell differentiation involved in tumor immune response
Cui Jiang et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2020)
The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumor-infiltrating T cells
Ailin Lepletier et al.
IMMUNOLOGY AND CELL BIOLOGY (2019)
Prognostic Values of CD38+CD101+PD1+CD8+ T Cells in Pancreatic Cancer
Mengjie Zhang et al.
IMMUNOLOGICAL INVESTIGATIONS (2019)
Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins
Elizaveta E. Alemasova et al.
NUCLEIC ACIDS RESEARCH (2019)
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
Triparna Sen et al.
CANCER DISCOVERY (2019)
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
Zebin Wang et al.
SCIENTIFIC REPORTS (2019)
JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti-PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect.
David Michael Hyman et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
DUO-O: A randomized phase Ill trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients.
Philipp Harter et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
ENGOT-OV44/FIRST study: A randomized, double-blind, adaptive, phase III study of platinum-based therapy with dostarlimab (TSR-042) + niraparib versus standard-of-care (SOC) platinum-based therapy as first-line treatment of stage 3/4 non-mucinous epithelial ovarian cancer (OC).
Anne-Claire Hardy-Bessard et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study
Anish Thomas et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
Constantia Pantelidou et al.
CANCER DISCOVERY (2019)
STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models
Weiqing Jing et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
Man Yee T. Keung et al.
JOURNAL OF CLINICAL MEDICINE (2019)
PARP-1 and its associated nucleases in DNA damage response
Yijie Wang et al.
DNA REPAIR (2019)
Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion
Anna M. Paczulla et al.
NATURE (2019)
The Multi-faceted Ecto-enzyme CD38: Roles in Immunomodulation, Cancer, Aging, and Metabolic Diseases
Kelly A. Hogan et al.
FRONTIERS IN IMMUNOLOGY (2019)
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
Shaveta Vinayak et al.
JAMA ONCOLOGY (2019)
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
Panagiotis A. Konstantinopoulos et al.
JAMA ONCOLOGY (2019)
DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes
Thiago Vidotto et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment
Grazia R. Tundo et al.
CHEMOTHERAPY (2019)
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial
Michael Friedlander et al.
LANCET ONCOLOGY (2019)
NAD plus consumption by PARP1 in response to DNA damage triggers metabolic shift critical for damaged cell survival
Michael M. Murata et al.
MOLECULAR BIOLOGY OF THE CELL (2019)
Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms
Ik Sun Kim et al.
NATURE CELL BIOLOGY (2019)
1191OPhase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
S Domchek et al.
ANNALS OF ONCOLOGY (2019)
PARP inhibition induces Akt-mediated cytoprotective effects through the formation of a mitochondria-targeted phospho-ATM-NEMO-Akt-mTOR signalosome
Antal Tapodi et al.
BIOCHEMICAL PHARMACOLOGY (2019)
PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
Jianfeng Shen et al.
CANCER RESEARCH (2019)
PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways
Yunlong Zhao et al.
IMMUNITY (2019)
PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow
Todd A. Hopkins et al.
MOLECULAR CANCER RESEARCH (2019)
Evading the STING: LKB1 Loss Leads to STING Silencing and Immune Escape in KRAS-Mutant Lung Cancers
Carminia Maria Della Corte et al.
CANCER DISCOVERY (2019)
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Jonathan J. Havel et al.
NATURE REVIEWS CANCER (2019)
JAVELIN ovarian PARP 100 study design: Phase III trial of avelumab plus chemotherapy followed by avelumab plus talazoparib maintenance in previously untreated epithelial ovarian cancer.
Ramez Nassef Eskander et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice
Di Zhang et al.
THERANOSTICS (2019)
CD38-NAD(+)Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response
Shilpak Chatterjee et al.
CELL METABOLISM (2018)
Anti-cancer therapy with TNFα and IFNγ:A comprehensive review
Jing Shen et al.
CELL PROLIFERATION (2018)
Functions of NKG2D in CD8+ T cells: an opportunity for immunotherapy
Kushal Prajapati et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2018)
Late Breaking Abstract An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC)
Y. Drew et al.
GYNECOLOGIC ONCOLOGY (2018)
A PET imaging agent for evaluating PARP-1 expression in ovarian cancer
Mehran Makvandi et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.
Michael Friedlander et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer
Tuo Li et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
The Importance of Poly(ADP-Ribose) Polymerase as a Sensor of Unligated Okazaki Fragments during DNA Replication
Hana Hanzlikova et al.
MOLECULAR CELL (2018)
Chromosomal instability drives metastasis through a cytosolic DNA response
Samuel F. Bakhoum et al.
NATURE (2018)
Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors
Thomas Duhen et al.
NATURE COMMUNICATIONS (2018)
NKG2D and Its Ligands: One for All, All for One
Alessandra Zingoni et al.
FRONTIERS IN IMMUNOLOGY (2018)
Targeting Cytosolic Nucleic Acid-Sensing Pathways for Cancer Immunotherapies
Sandra Iurescia et al.
FRONTIERS IN IMMUNOLOGY (2018)
Mechanisms for stalled replication fork stabilization: new targets for synthetic lethality strategies in cancer treatments
Hongwei Liao et al.
EMBO REPORTS (2018)
TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib plus pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)-Results from ROC cohort.
Panagiotis A. Konstantinopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
Diana Miao et al.
NATURE GENETICS (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Natural Killer Cells: Development, Maturation, and Clinical Utilization
Alex M. Abel et al.
FRONTIERS IN IMMUNOLOGY (2018)
The Emerging Role of CD8+ Tissue Resident Memory T (TRM) Cells in Antitumor Immunity: A Unique Functional Contribution of the CD103 Integrin
Stephanie Corgnac et al.
FRONTIERS IN IMMUNOLOGY (2018)
Resident memory T cells, critical components in tumor immunology
Fathia Mami-Chouaib et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Development of PARP and Immune-Checkpoint Inhibitor Combinations
Ross A. Stewart et al.
CANCER RESEARCH (2018)
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
Christopher S. Garris et al.
IMMUNITY (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
Stephanie Vairy et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
Liya Ding et al.
CELL REPORTS (2018)
Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
Isabella Faraoni et al.
CANCERS (2018)
Unraveling the Complex Interplay Between T Cell Metabolism and Function
Ramon I. Klein Geltink et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 36 (2018)
The role of neoantigen in immune checkpoint blockade therapy
Ming Yi et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2018)
The DNA damage response in immunotherapy and radiation
Robert M. Samstein et al.
ADVANCES IN RADIATION ONCOLOGY (2018)
Combining DNA damaging therapeutics with immunotherapy: more haste, less speed
Jessica S. Brown et al.
BRITISH JOURNAL OF CANCER (2018)
Small-Molecule Inhibition of PD-1 Transcription Is an Effective Alternative to Antibody Blockade in Cancer Therapy
Alison Taylor et al.
CANCER RESEARCH (2018)
A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia
Keith W. Pratz et al.
CLINICAL CANCER RESEARCH (2017)
A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia
Ivana Gojo et al.
CLINICAL CANCER RESEARCH (2017)
Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
Eileen E. Parkes et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
Valsamo Anagnostou et al.
CANCER DISCOVERY (2017)
Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and γδ T cell-mediated lysis in multiple myeloma
Chao Niu et al.
ONCOTARGET (2017)
Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
Eileen E. Parkes et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets
Bertrand Allard et al.
IMMUNOLOGICAL REVIEWS (2017)
Synthesis of the Ca2+ - mobilizing messengers NAADP and cADPR by intracellular CD38 enzyme in the mouse heart: Role in β-adrenoceptor signaling
Wee K. Lin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
Jung-Min Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Expression of CD226 is associated to but not required for NK cell education
Arnika K. Wagner et al.
NATURE COMMUNICATIONS (2017)
DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
Hiro Sato et al.
NATURE COMMUNICATIONS (2017)
Regulation of Serine-Threonine Kinase Akt Activation by NAD+-Dependent Deacetylase SIRT7
Jia Yu et al.
CELL REPORTS (2017)
Cd226-/- natural killer cells fail to establish stable contacts with cancer cells and show impaired control of tumor metastasis in vivo
Ji Sung Kim et al.
ONCOIMMUNOLOGY (2017)
Phase I study combining olaparib and tremelimumab for the treatment of women with BRCA-deficient recurrent ovarian cancer.
Sarah Foster Adams et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
NF-kappa B signaling in inflammation
Ting Liu et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2017)
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Shiping Jiao et al.
CLINICAL CANCER RESEARCH (2017)
AKT/PKB Signaling: Navigating the Network
Brendan D. Manning et al.
CELL (2017)
T Cell Fate at the Single-Cell Level
Veit R. Buchholz et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 34 (2016)
Immunoreceptor TIGIT inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with CD155
Baofu Zhang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
TGFβ Signaling Intersects with CD103 Integrin Signaling to Promote T-Lymphocyte Accumulation and Antitumor Activity in the Lung Tumor Microenvironment
Marie Boutet et al.
CANCER RESEARCH (2016)
A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy
Mehran Makvandi et al.
CANCER RESEARCH (2016)
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Joseph L. Benci et al.
CELL (2016)
The DNA Structure-Specific Endonuclease MUS81 Mediates DNA Sensor STING-Dependent Host Rejection of Prostate Cancer Cells
Samantha S. W. Ho et al.
IMMUNITY (2016)
Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8+ Cytolytic T Cell Responses
Alison Taylor et al.
IMMUNITY (2016)
The host STING pathway at the interface of cancer and immunity
Leticia Corrales et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic
Aniello Cerrato et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2016)
TIGIT-CD155 Interactions in Melanoma: A Novel Co-Inhibitory Pathway with Potential for Clinical Intervention
Karsten Mahnke et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase
Takashi Inozume et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
Expression of DNAM-1 (CD226) on inflammatory monocytes
Anh Van Vo et al.
MOLECULAR IMMUNOLOGY (2016)
A 17-gene stemness score for rapid determination of risk in acute leukaemia
Stanley W. K. Ng et al.
NATURE (2016)
A molecular threshold for effector CD8+ T cell differentiation controlled by transcription factors Blimp-1 and T-bet
Annie Xin et al.
NATURE IMMUNOLOGY (2016)
Ezrin Is Associated with Disease Progression in Ovarian Carcinoma
Vered Horwitz et al.
PLOS ONE (2016)
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
Yves Pommier et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Chia-Wei Li et al.
NATURE COMMUNICATIONS (2016)
LKB1 is a DNA damage response protein that regulates cellular sensitivity to PARP inhibitors
Yi-Shu Wang et al.
ONCOTARGET (2016)
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
Kyle C. Strickland et al.
ONCOTARGET (2016)
Polyfunctional Melan-A-specific tumor-reactive CD8+ T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS
Ornella Franzese et al.
ONCOIMMUNOLOGY (2016)
A first-in-human phase I trial of NKG2D chimeric antigen receptor-T cells in AML/MDS and multiple myeloma
Sarah Nikiforow et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?
Luca Paglialunga et al.
ESMO OPEN (2016)
The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1-/- murine model of ovarian cancer
Jing Huang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan Robinson et al.
CELL (2015)
NAD+ Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus
Carles Canto et al.
CELL METABOLISM (2015)
CD73 and CD39 ectonucleotidases in T cell differentiation: Beyond immunosuppression
Maria Rosa Bono et al.
FEBS LETTERS (2015)
The Transcription Factor NFAT Promotes Exhaustion of Activated CD8+ T Cells
Gustavo J. Martinez et al.
IMMUNITY (2015)
Poly(ADP-ribosyl)ation of FOXP3 Protein Mediated by PARP-1 Protein Regulates the Function of Regulatory T Cells
Xuerui Luo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients
Joe-Marc Chauvin et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
DNAM-1 controls NK cell activation via an ITT-like motif
Zhanguang Zhang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Coordinated Expression of DNAM-1 and LFA-1 in Educated NK Cells
Monika Enqvist et al.
JOURNAL OF IMMUNOLOGY (2015)
Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer
Hidenobu Ishii et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4+ T cell function
Mohamed A. Ghonim et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder
Bo Wang et al.
JOURNAL OF UROLOGY (2015)
Recent Advances in Discovering the Role of CCL5 in Metastatic Breast Cancer
Ayesha Khalid et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2015)
Strain-dependent Lethal Toxicity in NKG2D Ligand-targeted CAR T-cell Therapy
Rachel C. Lynn et al.
MOLECULAR THERAPY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The Microsatellite Instable Subset of Colorectal Cancer Is a Particularly Good Candidate for Checkpoint Blockade Immunotherapy
Yanping Xiao et al.
CANCER DISCOVERY (2015)
DNAM-1 Expression Marks an Alternative Program of NK Cell Maturation
Ludovic Martinet et al.
CELL REPORTS (2015)
NKG2D Receptor and Its Ligands in Host Defense
Lewis L. Lanier
CANCER IMMUNOLOGY RESEARCH (2015)
Effect of NKG2D ligand expression on host immune responses
Marine Champsaur et al.
IMMUNOLOGICAL REVIEWS (2015)
Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations
Yaser R. Hussein et al.
MODERN PATHOLOGY (2015)
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
Nicolas J. Llosa et al.
CANCER DISCOVERY (2015)
STING: infection, inflammation and cancer
Glen N. Barber
NATURE REVIEWS IMMUNOLOGY (2015)
The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers
Helen Cavanagh et al.
HEREDITARY CANCER IN CLINICAL PRACTICE (2015)
Trapping Poly(ADP-Ribose) Polymerase
Yuqiao Shen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8+ T Cell Effector Function
Robert J. Johnston et al.
CANCER CELL (2014)
The DNA damage response induces antigen presenting cell-like functions in fibroblasts
Melissa Li Fang Tang et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2014)
ERM proteins in cancer progression
Jarama Clucas et al.
JOURNAL OF CELL SCIENCE (2014)
Cytosolic-DNA-Mediated, STING-Dependent Proinflammatory Gene Induction Necessitates Canonical NF-κB Activation through TBK1
Takayuki Abe et al.
JOURNAL OF VIROLOGY (2014)
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Junko Murai et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Jonathan Ledermann et al.
LANCET ONCOLOGY (2014)
Molecular regulation of effector and memory T cell differentiation
John T. Chang et al.
NATURE IMMUNOLOGY (2014)
The Inflammatory Chemokine CCL5 and Cancer Progression
Donatella Aldinucci et al.
MEDIATORS OF INFLAMMATION (2014)
PARP-2 and PARP-3 are selectively activated by 5' phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1
Marie-France aEuro Langelier et al.
NUCLEIC ACIDS RESEARCH (2014)
Defect in HSP90 expression in highly differentiated human CD8+ T lymphocytes
O. Franzese et al.
CELL DEATH & DISEASE (2014)
Family-wide analysis of poly(ADP-ribose) polymerase activity
Sejal Vyas et al.
NATURE COMMUNICATIONS (2014)
PARP1-Driven Poly-ADP-Ribosylation Regulates BRCA1 Function in Homologous Recombination-Mediated DNA Repair
Yiduo Hu et al.
CANCER DISCOVERY (2014)
ARTD1/PARP1 Negatively Regulates Glycolysis by Inhibiting Hexokinase 1 Independent of NAD+ Depletion
Elise Fouquerel et al.
CELL REPORTS (2014)
PARP-1 regulates expression of TGF-β receptors in T cells
Pin Zhang et al.
BLOOD (2013)
Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells
S. Liu et al.
CELL DEATH AND DIFFERENTIATION (2013)
CCR1/CCL5 interaction promotes invasion of taxane-resistant PC3 prostate cancer cells by increasing secretion of MMPs 2/9 and by activating ERK and Rac signaling
Taku Kato et al.
CYTOKINE (2013)
The CD226/CD155 Interaction Regulates the Proinflammatory (Th1/Th17)/Anti-Inflammatory (Th2) Balance in Humans
Ester Lozano et al.
JOURNAL OF IMMUNOLOGY (2013)
TGF-β: Guardian of T Cell Function
Soyoung A. Oh et al.
JOURNAL OF IMMUNOLOGY (2013)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
PARP-1 Controls Immunosuppressive Function of Regulatory T Cells by Destabilizing Foxp3
Pin Zhang et al.
PLOS ONE (2013)
A systematic analysis of the PARP protein family identifies new functions critical for cell physiology
Sejal Vyas et al.
NATURE COMMUNICATIONS (2013)
Role of PI3K/Akt signaling in memory 038 T cell differentiation
Eui Ho Kim et al.
FRONTIERS IN IMMUNOLOGY (2013)
Beyond DNA repairs additional functions of PARP-1 in cancer
Alice N. Weaver et al.
FRONTIERS IN ONCOLOGY (2013)
Molecular mechanisms of T cell co-stimulation and co-inhibition
Lieping Chen et al.
NATURE REVIEWS IMMUNOLOGY (2013)
The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art
Mike De Vos et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Catalysis-Based Inhibitors of the Calcium Signaling Function of CD38
Anna Ka Yee Kwong et al.
BIOCHEMISTRY (2012)
Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91phox expression and the PARP-1/PAR pathway of apoptosis
Johan Aurelius et al.
BLOOD (2012)
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai et al.
CANCER RESEARCH (2012)
CDK2-dependent activation of PARP-1 is required for hormonal gene regulation in breast cancer cells
Roni H. G. Wright et al.
GENES & DEVELOPMENT (2012)
Comprehensive Analysis of NKG2D Ligand Expression and Release in Leukemia: Implications for NKG2D-Mediated NK Cell Responses
Julia Hilpert et al.
JOURNAL OF IMMUNOLOGY (2012)
The TIGIT/CD226 Axis Regulates Human T Cell Function
Ester Lozano et al.
JOURNAL OF IMMUNOLOGY (2012)
PARP-1 Modulation of mTOR Signaling in Response to a DNA Alkylating Agent
Chantal Ethier et al.
PLOS ONE (2012)
STING Specifies IRF3 Phosphorylation by TBK1 in the Cytosolic DNA Signaling Pathway
Yasuo Tanaka et al.
SCIENCE SIGNALING (2012)
Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
Lauren Averett Byers et al.
CANCER DISCOVERY (2012)
PARP-1 deficiency blocks IL-5 expression through calpain-dependent degradation of STAT-6 in a murine asthma model
R. Datta et al.
ALLERGY (2011)
NKG2D performs two functions in invariant NKT cells: Direct TCR-independent activation of NK-like cytolysis and co-stimulation of activation by CD1d
Carlotta Kuylenstierna et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
Protein Kinase B Controls Transcriptional Programs that Direct Cytotoxic T Cell Fate but Is Dispensable for T Cell Metabolism
Andrew N. Macintyre et al.
IMMUNITY (2011)
PARP regulates nonhomologous end joining through retention of Ku at double-strand breaks
C. Anne-Marie Couto et al.
JOURNAL OF CELL BIOLOGY (2011)
Randomized Phase II Trials: A Long-term Investment With Promising Returns
Manish R. Sharma et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
Anand G. Patel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Metabolism, migration and memory in cytotoxic T cells
David Finlay et al.
NATURE REVIEWS IMMUNOLOGY (2011)
DNAM-1/CD155 Interactions Promote Cytokine and NK Cell-Mediated Suppression of Poorly Immunogenic Melanoma Metastases
Christopher J. Chan et al.
JOURNAL OF IMMUNOLOGY (2010)
Increased Foxp3+ Regulatory T Cells in Poly(ADP-Ribose) Polymerase-1 Deficiency
Francesca Nasta et al.
JOURNAL OF IMMUNOLOGY (2010)
The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets
Raga Krishnakumar et al.
MOLECULAR CELL (2010)
Functional Dichotomy between NKG2D and CD28-Mediated Co-Stimulation in Human CD8+ T Cells
Kamalakannan Rajasekaran et al.
PLOS ONE (2010)
Identification of Therapeutic Targets for Quiescent, Chemotherapy-Resistant Human Leukemia Stem Cells
Yoriko Saito et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Environmental exposures and mutational patterns of cancer genomes
Gerd P. Pfeifer
GENOME MEDICINE (2010)
PARP inhibition: PARP1 and beyond
Michele Rouleau et al.
NATURE REVIEWS CANCER (2010)
NFAT, immunity and cancer: a transcription factor comes of age
Martin R. Mueller et al.
NATURE REVIEWS IMMUNOLOGY (2010)
CCL5 increases lung cancer migration via PI3K Akt and NF-kappa B pathways
Chun-Yin Huang et al.
BIOCHEMICAL PHARMACOLOGY (2009)
Immunoregulatory functions of KLRG1 cadherin interactions are dependent on forward and reverse signaling
Cindy Banh et al.
BLOOD (2009)
KLRG1 signaling induces defective Akt (ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8+ T cells
Sian M. Henson et al.
BLOOD (2009)
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
Ana M. Mendes-Pereira et al.
EMBO MOLECULAR MEDICINE (2009)
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
Noa Stanietsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Transcriptional regulation by Poly(ADP-ribose) polymerase-1 during T cell activation
Luis Saenz et al.
BMC GENOMICS (2008)
Integrin-Linked Kinase Regulates E-Cadherin Expression Through PARP-1
Timothy R. McPhee et al.
DEVELOPMENTAL DYNAMICS (2008)
LYR71, a derivative of trimeric resveratrol, inhibits tumorigenesis by blocking STAT3-mediated matrix metalloproteinase 9 expression
Ja Eun Kim et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2008)
PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA
Kazuto Sugimura et al.
JOURNAL OF CELL BIOLOGY (2008)
Accelerated tumor growth in mice deficient in DNAM-1 receptor
Akiko Iguchi-Manaka et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates
Surojit Sarkar et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Regulation of transcription factor NFAT by ADP-ribosylation
Opeyemi A. Olabisi et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
Regulation of NFAT by poly (ADP-ribose) polymerase activity in T cells
Rut Valdor et al.
MOLECULAR IMMUNOLOGY (2008)
NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways
Dirk H. J. Verhoeven et al.
MOLECULAR IMMUNOLOGY (2008)
AKT is activated in an ataxia-telangiectasia and Rad3-related-dependent manner in response to temozolomide and confers protection against drug-induced cell growth inhibition
Simona Caporali et al.
MOLECULAR PHARMACOLOGY (2008)
STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling
Hiroki Ishikawa et al.
NATURE (2008)
IL-4 inhibits TGF-β-induced Foxp3+ T cells and, together with TGF-β, generates IL-9+ IL-10+ Foxp3- effector T cells
Valerie Dardalhon et al.
NATURE IMMUNOLOGY (2008)
The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells
Yasser M. El-Sherbiny et al.
CANCER RESEARCH (2007)
Inflammation directs memory precursor and short-lived effector CD8+ T cell fates via the graded expression of T-bet transcription factor
Nikhil S. Joshi et al.
IMMUNITY (2007)
Poly(ADP-ribose) polymerase 1 accelerates single-strand break repair in concert with poly(ADP-ribose) glycohydrolase
Anna E. O. Fisher et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
The loss of telomerase activity in highly differentiated CD8+CD28-CD27- T cells is associated with decreased Akt (Ser473) phosphorylation
Fiona J. Plunkett et al.
JOURNAL OF IMMUNOLOGY (2007)
Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction
Cyril Fauriat et al.
BLOOD (2007)
PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways
Minli Wang et al.
NUCLEIC ACIDS RESEARCH (2006)
Regulation of SIRT 1 mediated NAD dependent deacetylation: A novel role for the multifunctional enzyme CD38
Pinar Aksoy et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
PARP-2 deficiency affects the survival of CD4+CD8+ double-positive thymocytes
Jose Yelamos et al.
EMBO JOURNAL (2006)
Regulation of intracellular levels of NAD: A novel role for CD38
Pinar Aksoy et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
GATA-3 promotes Th2 responses through three different mechanisms: induction of Th2 cytokine production, selective growth of Th2 cells and inhibition of Th1 cell-specific factors
JF Zhu et al.
CELL RESEARCH (2006)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
The DnaJ-related factor Mrj interacts with nuclear factor of activated T cells c3 and mediates transcriptional repression through class II histone deacetylase recruitment
YS Dai et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy
T Helleday et al.
CELL CYCLE (2005)
Costimulation through NKG2D enhances murine CD8+ CTL function:: Similarities and differences between NKG2D and CD28 costimulation
MA Markiewicz et al.
JOURNAL OF IMMUNOLOGY (2005)
NFAT proteins: Key regulators of T-cell development and function
F Macian
NATURE REVIEWS IMMUNOLOGY (2005)
Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence
Y Hirose et al.
CANCER RESEARCH (2005)
Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias
P Nowbakht et al.
BLOOD (2005)
Cutting edge:: NKG2D is a costimulatory receptor for human naive CD8+ T cells
K Maasho et al.
JOURNAL OF IMMUNOLOGY (2005)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: Critical role of DNAX accessory molecule-1-poliovirus receptor interaction
R Castriconi et al.
CANCER RESEARCH (2004)
Hallmarks of 'BRCAness' in sporadic cancers
N Turner et al.
NATURE REVIEWS CANCER (2004)
CD226 (DNAM-1) is involved in lymphocyte function-associated antigen 1 costimulatory signal for naive T cell differentiation and proliferation
K Shibuya et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2
MC King et al.
SCIENCE (2003)
Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients
J Moilanen et al.
GYNECOLOGIC ONCOLOGY (2003)
The PI-3 kinase/Akt pathway and T cell activation:: pleiotropic pathways downstream of PIP3
LP Kane et al.
IMMUNOLOGICAL REVIEWS (2003)
CD103+ intraepithelial lymphocytes -: a unique population in microsatellite unstable sporadic colorectal cancer
E Quinn et al.
EUROPEAN JOURNAL OF CANCER (2003)
NFATc2-mediated repression of cyclin-dependent kinase 4 expression
S Baksh et al.
MOLECULAR CELL (2002)
The role of the NKG2D immunoreceptor in immune cell activation and natural killing
AM Jamieson et al.
IMMUNITY (2002)
NFAT signaling: Choreographing the social lives of cells
GR Crabtree et al.
CELL (2002)
Molecular competition for NKG2D: H60 and RAE1 compete unequally for NKG2D with dominance of H60
CA O'Callaghan et al.
IMMUNITY (2001)
Partners in transcription:: NFAT and AP-1
F Macián et al.
ONCOGENE (2001)
Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages
A Diefenbach et al.
NATURE IMMUNOLOGY (2000)
Share Paper
